Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment that could end up competing with Zepbound from Eli Lilly.

Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?

Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.

Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?

Viking Therapeutics is advancing VK2735 directly to Phase 3 trials, bypassing Phase 2b. The company faces intense competition from larger players like Novo Nordisk and Eli Lilly. Viking has a solid cash position but might encounter financial challenges sooner than expected.

Viking Therapeutics: Leaping Ahead In The Weight-Loss Race

Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.

Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed

Viking Therapeutics has a high valuation for a company with no sales. Novo Nordisk is competing in the same market, and that market is growing rapidly.

Could Viking Therapeutics Become the Next Novo Nordisk?

Altimmune

Structure Therapeutics Inc

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.

3 Promising Biotech Stocks for the Long-Term: August 2024

Pfizer

Roche Holding AG

The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight loss space.

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.

Eli Lilly

Novo Nordisk

Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressable market.

What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.

Viking Therapeutics has a powerful weight loss candidate in late-stage trials. Zealand Pharma has a handful of programs and a powerful collaborator.

Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma

Sterling Construction

Trupanion

These overlooked breakout stocks may not grab headlines, but they can deliver stellar returns. Investors must diversify their portfolios with lesser-known companies from time to time.

3 Overlooked Stocks Poised for a Breakout Very Soon

Iovance Biotherapeutics

The cost of taking out fresh debt is an important consideration for some biotechs. There's reason to believe that debt financing is about to get a bit cheaper.

Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.

The upstart biotech just reported its Q2 earnings -- and investors were pleased. All of its programs are proceeding according to plan, and it isn't spending much.

The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.

Artificial intelligence (AI) chip leader Nvidia has soared 126% so far this year -- but this biotech stock has advanced even more. This biotech player is targeting a market that could be worth $100 billion by the end of the decade.

Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.

Viking is developing drug candidates in an area of high interest and growth: weight loss. The company is launching a phase 3 clinical trial for its first weight loss candidate.

Is Viking Therapeutics a Millionaire-Maker Stock?

Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise.

Pharmaceutical stocks to watch for end of 2024

Eli Lilly (LLY) and Novo Nordisk (NVO) shares lost ground, while shares of drugmaker Viking Therapeutics (VKTX) soared in intraday trading Thursday after the company reported advances in trials of its weight-loss drugs that could challenge the dominance of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.

Why Viking's Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks

Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and the Viking Therapeutics' analyst community.

Viking Therapeutics: Pharma Stock Soars on Positive Earnings

Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.

Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates

Viking Therapeutics plans to advance its obesity drug VK2735 into late-stage clinical testing. VK2735 could be a formidable rival to Lilly's Zepbound and Novo Nordisk's Wegovy if it's approved.

Why Viking Therapeutics Stock Is Skyrocketing Today

Viking Therapeutics, Inc. provided a better-than-expected pipeline update when it reported second quarter earnings. Subcutaneous VK2735 will advance straight into a phase 3 trial, and this should speed up its potential market arrival by at least 18–24 months. Oral VK2735 has advanced to the 100mg cohort, with management making positive remarks about tolerability in the 60mg and 80mg dose cohorts.

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug.

Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk

Shares of Viking Therapeutics jumped on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected.  It brings the drugmaker one step closer to joining the highly popular market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade.

Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial

Viking Therapeutics (NASDAQ: VKTX ) stock is heading higher on Thursday as the clinical-stage biopharmaceutical company prepares to start another trial for its weight loss drug. Viking Therapeutics says that it's ready to progress subcutaneous VK2735 into a Phase 3 clinical trial as a treatment for obesity and other metabolic disorders.

Viking Therapeutics (VKTX) Stock Pops on Plans to Start Late-Stage Weight Loss Drug Trials

Li Auto Inc.

Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unavailable to regular investors, they are nonetheless guesses.

Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q2 2024 Earnings Conference Call July 24, 2024 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Asim Rana - Truist Securities Steve Seedhouse - Raymond James Jay Olson - Oppenheimer Annabel Samimy - Stifel Roger Song - Jefferies Andrew Hsieh - William Blair Rohit Bhasin - Morgan Stanley Justin Zelin - BTIG Thomas Smith - Leerink Partners Yale Jen - Laidlaw Company Operator Welcome to the Viking Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

News for Viking Therapeutics Stock (VKTX)